“If we look at that two billion doses, over 75% of it has gone to just 10 countries. And in fact three countries China, the U.S. and India account for about 60% of those doses,” Bruce Aylward said
SII plans to seek restricted emergency use permission of the vaccine in India. The DCGI has granted permission to the Serum Institute of India (SII) to manufacture the Sputnik COVID-19 vaccine in India for examination, test and analysis with certain conditions, official sources said on Friday. The Pune-based firm has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow in Russia for developing Sputnik V at its licensed Hadapsar facility. “The DCGI has granted permission to the Serum Institute to manufacture the Sputnik COVID-19 vaccine in India for examination, test and analysis at its licensed Hadapsar facility with certain conditions,” an official source said.